Profile

David M. Reboussin, Ph.D.Wake Forest Baptist Health

David M. Reboussin, Ph.D.

Professor,

Contact Information

Academic: 336-716-6844 | Department: 336-716-2011

Email: drebouss@wakehealth.edu

Education & Training

  • B.A., Pomona College , 1982
  • Ph.D., University of Wisconsin-Madison , 1992
  • M.S., University of Chicago , 1984

Memberships

  • Royal Statistical Society
  • Soc Of Clinical Trial Research
  • Am Statistical Assoc
  • Biometric Society
David M. Reboussin, Ph.D.Wake Forest Baptist Health

David M. Reboussin, Ph.D.

Professor, Department of Biostatistics

Research Interests

diabetes, genetics/genome, obesity, sleep research

Contact Information

Academic: 336-716-6844 | Department: 336-716-2011

Email: drebouss@wakehealth.edu

Recent Publications

Peter I, Papandonatos GD, Belalcazar LM, Yang Y, Erar B, Jakicic JM, Unick JL, Balasubramanyam A, Lipkin EW, Delahanty LM, Wagenknecht LE, Wing RR, McCaffery JM, Huggins GS, Espeland MA, Reboussin D, et al. Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. Med Sci Sports Exerc. 2014;46(2):302-311.

Fitzpatrick SL, Jeffery R, Johnson KC, Roche CC, Van Dorsten B, Gee M, Dotson K, Walkup MP, Espeland MA, Bahnson JL, Wagenknecht LE, Reboussin D, Rejeski WJ, Bertoni AG, Lang W, Lawlor MS, Lefkowitz D, Miller GD, Reynolds PS, Ribisl PM,. Baseline predictors of missed visits in the Look AHEAD study. Obesity (Silver Spring). 2014;22(1):131-140.

Vaughn McCall W, Reboussin D, Prudic J, Haskett RF, Isenberg K, Olfson M, Rosenquist PB, Sackeim HA. Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. J Affect Disord. 2013;147(1-3):107-111.

Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP, Zammit G, Newman AB, Wadden TA, Jakicic JM, Wing RR, Pi-Sunyer FX, Foster GD. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641-649.

Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM,. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.

Wing RR, Reboussin D, Lewis CE. Intensive lifestyle intervention in type 2 diabetes [reply to letter]. N Engl J Med. 2013;369(24):2358-2359.

McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Kahn SE, Knowler WC, Hudnall GE, Lipkin EW, Kitabchi AE, Wagenknecht LE, Espeland MA, Bahnson JL, Reboussin D, Rejeski WJ, Bertoni A,. FTO predicts weight regain in the Look AHEAD clinical trial. Int J Obes (Lond). 2013;37(12):1545-1552.

Mount DL, Davis C, Kennedy B, Raatz S, Dotson K, Gary-Webb TL, Thomas S, Johnson KC, Espeland MA, Bahnson J, Wagenknecht L, Reboussin D, Rejeski WJ, Lang W, Bertoni A, Vitolins M, Miller G, Ribisl P, Hodges A,. Factors influencing enrollment of African Americans in the Look AHEAD trial. Clin Trials. 2012;9(1):80-89.

Faulconbridge LF, Wadden TA, Rubin RR, Wing RR, Walkup MP, Fabricatore AN, Coday M, Van Dorsten B, Mount DL, Ewing LJ, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Lang W, Miller G, Lefkowitz D,. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity (Silver Spring). 2012;20(4):783-793.

Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peters AL, Walkup MP, Hodges A, Williams CC, Bray GA, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Lang W, Miller G, Lefkowitz D, Reynolds PS,. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619-627.

Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, Kitabchi AE, Faulconbridge LF, Kitzman DW, Espeland MA. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring). 2012;20(10):2048-2056.

Belalcazar LM, Ballantyne CM, Lang W, Rushing J, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Miller G, Lefkowitz D, Reynolds PS, Ribisl P, Vitolins M, Booth M, Dotson KM, Hodges A, Williams CC,. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the Look AHEAD study. Arterioscler Thromb Vasc Biol. 2011;31(7):1689-1695.

Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC, Hoogeveen RC, Pi-Sunyer FX, Ballantyne CM. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33(1):197-199.


Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH. Relationships of serum free thyroxine and erythrocyte measures in euthyroid HFE C282Y homozygotes and control subjects: the HEIRS study. Int J Lab Hematol. 2010;32(3):282-287.

Mychaleckyj JC, Noble JA, Moonsamy PV, Carlson JA, Varney MD, Post J, Pierce JJ, Williams DT, Perdue LH, Reboussin DM, et al. HLA genotyping in the international Type 1 Diabetes Genetics Consortium. Clin Trials. 2010;7(Suppl 1):S75-S87.

Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, Tracy RP, Pi-Sunyer FX, Ballantyne CM. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33(11):2297-2303.

Wing RR, Bahnson JL, Bray GA, Clark JM, Coday M, Egan C, Espeland MA, Reboussin D, Rejeski WJ, Wagenknecht L, et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.

Kramer H, Reboussin D, Bertoni AG, Marcovina S, Lipkin E, Greenway FL III, Brancati FL. Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care. 2009;32(5):851-853.

Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath K, Schaefer EJ, Asztalos BF. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis. 2009;205(1):325-330.

Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, Wadden TA, Kelley D, Wing RR, Reboussin D, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619-1626.

Adams PC, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively BM, et al. Screening for iron overload: lessons from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Can J Gastroenterol. 2009;23(11):769-772.

Belalcazar M, Reboussin D, Haffner S, Hoogeveen R, Tracy R, Kriska A, Schwenke D, Pi-Sunyer X, Ballantyne C. Improvement in glucose control with lifestyle intervention reduces C-reactive protein in obese subjects with type 2 diabetes: the Look AHEAD Study [abstract]. Circulation. 2009;120(18 Suppl 2):S473-S474.

McLaren CE, Garner CP, Constantine CC, Masle S, Vulpe CD, Snively BM, Cook JD, Nickerson DA, Leiendecker-Foster C, Reboussin DM, et al. Genome-wide association study identifies genetic loci associated with iron deficiency [abstract]. Blood. 2009;114(22):1552-1553.

Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, Eckfeldt JH, McLaren CE, Reiss JA, McLaren GD, Reboussin DM, et al. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol. 2008;83(2):126-132.

McLaren CE, Gordeuk VR, Chen W-P, Barton JC, Acton RT, Speechley M, Castro O, Adams PC, Snively BM, Reboussin DM, et al. Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Transl Res. 2008;151(2):97-109.

Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28(3):575-579.

Adams PC, Reboussin DM, Barton JC, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, et al. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Int J Lab Hematol. 2008;30(4):300-305.

Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH. Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study. Thyroid. 2008;18(8):831-838.

Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, Reiss JA, Adams PC, Passmore L, et al. Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol. 2008;83(8):618-626.

McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Snively BM, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008;22(11):923-930.

Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington DM. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause. 2008;15(6):1060-1064.


Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Passmore LV, et al. Serum ferritin and transferrin saturation in Asians and pacific islanders. Arch Intern Med. 2007;167(7):722-726.

Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, Press RD, Adams PC, Reboussin DM, et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007;38(3):247-252.

Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins RW, Lovato L, et al. Non-fasting serum transferrin saturation (TS) is similar to fasting TS for the detection of C282Y homozygotes for hemochromatosis [abstract]. Am J Hematol. 2007;82(6):575.

Adams PC, Reboussin DM, Barton JC, McLaren CE, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren GD, et al. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study [abstract]. Am J Hematol. 2007;82(6):595-596.

McLaren CE, Harris EL, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Passmore LV, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders living in the U.S. and Canada: the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Am J Hematol. 2007;82(6):574.

McLaren GD, Gordeuk VR, Reboussin DM, Barton JC, Acton RT, McLaren CE, Harris EL, Reiss JA, Adams PC, Passmore L, et al. Serum ferritin concentration and body iron stores among 101,168 primary care participants [abstract]. Am J Hematol. 2007;82(6):594-595.

McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, Acton RT, Ruggiero AM, et al. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Am J Hematol. 2007;82(10):898-905.

Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Lovato L, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007;120(11):999.e1-7.

Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, et al. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007;11(3):269-275.

McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley M, Snively BM, et al. Symptoms, signs, and clinical conditions in HFE C282Y homozygotes identified by screening in primary care [abstract]. Am J Hematol. 2007;82(6):553.

Adams PC, Reboussin DM, Barton JC, Gordeuk VR, Leiendecker-Foster C, McLaren CE, Acton RT, Eckfeldt JH, Dawkins FW, Snively BM, et al. Iron removed by quantitative phlebotomy in participants identified from a multi-ethnic, primary care sample [abstract]. Am J Hematol. 2007;82(6):558.

Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC, McIaren GD, Eckfeldt JH, Dawkins FW, Gordeuk VR, et al. Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol. 2006;4(7):918-923.

Espeland MA, Bahnson J, Wagenknecht, Reboussin D, Rejeski WJ, Lang W, Bertoni A, Vitolins M, Miller G, Ribisl P, Dotson K, Hodges A, Hogan P, et al. The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737-752.

McLaren CE, Li K-T, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, et al. Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. Transl Res. 2006;148(4):196-206.

Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care. 2006;29(9):2084-2089.

Lamon-Fava S, Mayer J, Herrington DM, Reboussin DM, Schaefer EJ, Asztalos BF, Mayer J. High density lipoprotein subpopulations and lipoprotein remnants: effects of hormonal replacement therapy and association with baseline coronary atherosclerosis in the Estrogen Replacement and Atherosclerosis (ERA) trial [abstract]. Circulation. 2006;114(18 Suppl):255.

Adams PC, Reboussin DM, McLaren CE, Barton JC, Acton RT, Lovato L, McLaren GD, Moses GC, Press R, Chang H, et al. Do the biological variability of transferrin saturation and unsaturated iron binding capacity limit their utility as screening tests for HFE C282Y-linked hemochromatosis? [abstract]. Hepatology. 2006;44(4 Suppl):432A-433A.

McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley M, Snively BM, et al. Symptoms and signs of hemochromatosis in HFE C282Y homozygotes identified by screening in primary care [abstract]. Blood. 2006;108(11 Pt 1):444a.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.